Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695002 | 0.79 | PDE4A (0.47) | PDE3BPDE3AKDM4EPKMPARP1 | |
| SCHEMBL2594045 | 0.77 | PDE3B (0.50) | PDE3BPDE3AKDM4EMAPK14 | |
| SCHEMBL1695218 | 0.69 | MAPK1 (0.46) | KDM4EPKMPARP1GAAMEN1 | |
| Hydrochloric Acid SCHEMBL1694763 | 0.68 | MAPK1 (0.44) | KDM4EPKMPARP1GAAMEN1 | |
| SCHEMBL16493428 | 0.66 | KDM4E (0.42) | KDM4EPKMPARP1GAAMEN1 | |
| SCHEMBL2594097 | 0.66 | KDM4E (0.46) | PDE3BPDE3AKDM4EPKMPARP1 | |
| SCHEMBL6042142 | 0.66 | NOTUM (0.77) | PDE3BPDE3ANOTUMALDH2MAP4K4 | |
| Hydrochloric Acid SCHEMBL2591197 | 0.65 | KDM4E (0.45) | PDE3BPDE3AKDM4EPKMPARP1 | |
| Hydrochloric Acid SCHEMBL21489626 | 0.65 | KDM4E (0.41) | KDM4EPKMPARP1GAAMEN1 | |
| SCHEMBL15781397 | 0.65 | GAA (0.51) | PDE3BPDE3ANOTUMALDH2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2018-07-26 | — | — | US | disclosed |
| US-9956210-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-05-01 | — | — | US | disclosed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | GLAXOSMITHKLINE LLC | 2017-04-06 | — | — | US | disclosed |
| US-9562041-B2 | Enhancer of zeste homolog 2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| EP-2646020-B1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9446041-B2 | Method of treatment | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| EP-2646020-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130245016-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-09-19 | — | — | US | disclosed |
| US-8536179-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2566328-A1 | INDAZOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2012075080-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2011140325-A1 | INDAZOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245016-A1 | INDOLES | IDO1, IDO2, INMT | PDE3B 1868/4885PDE3A 2241/4885NOTUM 3520/4885 |
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | PDE3B 1430/4885PDE3A 1639/4885NOTUM 2219/4885 |
| US-20180207144-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | PDE3B 4215/4885PDE3A 4305/4885NOTUM 2759/4885 |
| US-20170095461-A1 | ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS | EZH2, EZH1, BMI1 | PDE3B 4215/4885PDE3A 4305/4885NOTUM 2759/4885 |
| US-10478426-B2 | Enhancer of Zeste Homolog 2 inhibitors | EZH2, EZH1, BMI1 | PDE3B 4215/4885PDE3A 4305/4885NOTUM 2759/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | PDE3B 1887/4885PDE3A 2267/4885NOTUM 3564/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | PDE3B 1868/4885PDE3A 2241/4885NOTUM 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.